Gamida Cell, an Israel-based developer of stem cells for healthcare treatments, has raised $10m in its series E round.
Alongside local corporations Teva Pharmaceutical Industries, Elbit Imaging and Clal Biotechnology Industries were venture capital firms Israel Healthcare Venture, Amgen, Denali Ventures and Auriga Ventures.
The company said it was seeking a strategic partner to join in the global commercialization of StemEx, an alternative therapeutic treatment for patients with blood cancers, such as leukemia and lymphoma, who can be cured by bone marrow transplantation but do not have a matched bone marrow donor.
StemEx is being developed by the Gamida Cell-TEVA joint venture and its phase III clinical trial completed enrollment in February.
Gamida previously raised $16m in its D round in September 2006.